News for Agent

Daily business news: funding, M&A, launches

Research & Clinical Trials

IRSF Funds Male Inclusion in Unravel Biosciences' REVOLUTION Rett Trial

By ·

Key takeaways

  • The International Rett Syndrome Foundation funded a protocol amendment to include males in Unravel Biosciences' REVOLUTION Phase 1 trial of RVL-001.
  • Colombia's CEICA ethics committee approved the amended protocol, with INVIMA regulatory approval anticipated in January 2027.
  • The amended protocol expands enrollment ages from 6 to 21 to ages 3 to 25 within the existing 15-participant target.
  • IRSF launched the $1 million MR. Males with Rett Fund in August 2026, and this is its first investment.

The International Rett Syndrome Foundation funded a protocol amendment to include males in Unravel Biosciences' REVOLUTION Phase 1 trial of RVL-001 for Rett syndrome, the foundation's first investment from its $1 million MR. Males with Rett Fund. EIN Presswire reported the funding on November 17, 2026.

How the REVOLUTION Amendment Changes Enrollment

Colombia's Clinical Research Ethics Committee of Antioquia (CEICA) approved the amended protocol, and separate regulatory approval from INVIMA is anticipated in January 2027. If approved, REVOLUTION would become only the second Rett syndrome clinical trial worldwide to open enrollment to males.

Unravel Biosciences is a clinical-stage biotech using its BioNAV platform and patient-derived RNA to repurpose existing drugs for rare diseases. The REVOLUTION study (NCT07150013) evaluates RVL-001, an investigational oral formulation of vorinostat, and began dosing in May 2026 at the PECET center in Medellín, Colombia. The placebo-controlled study was designed for 15 participants ages 6 to 21; the amendment expands the age range to 3 to 25 and allows males within that existing target.

"Male inclusion cannot remain an afterthought in Rett syndrome research," said Laura Hameed, CEO of IRSF. "We launched the MR. Fund to change who gets considered, who gets studied, and ultimately who may benefit from new treatments."

Unravel's Funding and Platform Records

According to akta.pro company records, Unravel Biosciences has five funding rounds on record, including a $1.6 million pre-seed in October 2021 led by RTK Group and a $550,000 grant in March 2023 led by Massachusetts General Hospital, for total funding of $3.3 million. The same records list a January 2026 product launch marking the first patient dosed in RVL-001 proof-of-concept studies for Rett syndrome and Pitt Hopkins syndrome in Colombia, with target enrollment of 15 Rett and 5 Pitt Hopkins patients and study completion anticipated in the first quarter of 2027.

Rett Work Alongside Other Rare-Disease Trials

Other rare-disease developers have reported trial updates in November 2026. Seeking Alpha reported on November 14 that the FDA reversed its support for natural-history controls in a uniQure Huntington's trial. STAT reported on November 10 that PepGen disclosed early data in myotonic dystrophy type 1 from a trial involving six patients treated for 12 weeks. PR Newswire reported on November 5 that Skyhawk Therapeutics dosed its first U.S. patients in the pivotal FALCON-HD study of SKY-0515 in Huntington's disease.

INVIMA Decision and Study Completion Dates

INVIMA's regulatory decision on the amended protocol is anticipated in January 2027. Unravel's proof-of-concept studies of RVL-001 in Rett syndrome and Pitt Hopkins syndrome carry anticipated completion in the first quarter of 2027, according to akta.pro company records.

Companies in this story

Sources

Machine-readable: Markdown · JSON